MHRA-LOGO.gif (6825 bytes) Medicines and Healthcare products
Regulatory Agency

Market Towers
1 Nine Elms Lane, London SW8 5NQ


Mr Charles Medawar
Social Audit Ltd
P.O. Box 111
London NW1 8XG

General enquiries
Telephone 020 7273 0000  Fax 020 7273 0353
E-mail [email protected]

Direct line:  020 7084 3523
Direct fax:  020 7084 2293

Email:   [email protected]

                                                                                            Date:   27 May 2005

Dear Mr Medawar,

Re:   Promotion of Efexor (venlafaxine) by Wyeth

Thank you for your letter dated 17 April 2005 concerning the current advertising for Efexor (venlafaxine) by Wyeth.

We have been in correspondence with the advertiser and I am writing to advise you of progress in the investigation to date. Upon receipt of your letter, the Advertising Unit undertook a preliminary investigation of the issues raised and wrote to Wyeth setting out our views. We also requested that use of the advert be immediately suspended pending the outcome of our investigations. Wyeth agreed to this. Wyeth attended the MHRA to discuss further action and our investigation is ongoing.

May I take this opportunity to reassure you that the Agency takes very seriously any complaint made to it and hope you will accept this interim response in that spirit. We will provide you a full response as soon as possible.

Yours sincerely,

Bronwen Forsyth
Scientific Assessor. Advertising
Post-Licensing Division